MENU
GNOM
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

GNOM stock forecast, quote, news & analysis

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index")... Show more

Category: #Health
GNOM
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for GNOM with price predictions
Sep 04, 2026

Momentum Indicator for GNOM turns negative, indicating new downward trend

GNOM saw its Momentum Indicator move below the 0 level on September 04, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 102 similar instances where the indicator turned negative. In of the 102 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for GNOM moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 70 cases where GNOM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GNOM turned negative on September 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNOM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GNOM broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GNOM advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 187 cases where GNOM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Illumina (NASDAQ:ILMN), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Market Cap

The average market capitalization across the Global X Genomics & Biotechnology ETF ETF is 18.36B. The market cap for tickers in the group ranges from 50.13M to 187.23B. GILD holds the highest valuation in this group at 187.23B. The lowest valued company is SGMO at 50.13M.

High and low price notable news

The average weekly price growth across all stocks in the Global X Genomics & Biotechnology ETF ETF was -1%. For the same ETF, the average monthly price growth was 14%, and the average quarterly price growth was 42%. ALNY experienced the highest price growth at 12%, while RARE experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Global X Genomics & Biotechnology ETF ETF was -15%. For the same stocks of the ETF, the average monthly volume growth was -17% and the average quarterly volume growth was 3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 63
Price Growth Rating: 41
SMR Rating: 82
Profit Risk Rating: 91
Seasonality Score: -24 (-100 ... +100)
View a ticker or compare two or three
GNOM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
Global X Funds600 Lexington Avenue, 20th FloorNew York
Phone
+1 8884938631
Web
www.globalxfunds.com